InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,858.84
(
0.28%
)
US TECH 100
19,678.80
(
0.22%
)
Dow Jones
43,173.22
(
0.22%
)
Brent Oil
74.18
(
-0.06%
)
Bitcoin
66,774.87
(
-1.25%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

bocxman

Send PM Follow Ignore
Followers 2
Posts 1054
Boards Moderated 0
Alias Born 03/03/2005

bocxman

Re: Headache post# 3277

Friday, 04/28/2006 12:26:39 AM

Friday, April 28, 2006 12:26:39 AM

Post# of 30387
Headache: IMO you're misreading it...first of all Abbott was willing to license serum RECAF in it's old form, so why wouldn't others? That's like saying Harvard will accept you but not the local City College.

BOCX was very clear that the decision to move to a new assay type as it related to potential licensees was based on having a position of LEVERAGE in negotiations. This tells me that they learned from the ABT experience that the big boys want a colorimetric assay so give them one.

DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up